Award & Investment Overview
The University of Colorado has awarded a combined $1.6 million in commercialization grants to 12 research teams through its 2026 Lab Venture Challenge (LVC), supporting the development of university-originated technologies across biosciences, physical sciences, and engineering.
Organized by Venture Partners at CU Boulder, the competition brings together innovators from CU Boulder, CU Denver, and CU Colorado Springs to advance research projects with identifiable commercial applications and credible pathways to market.
The awards are funded through the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Program, with matching funds from Venture Partners at CU Boulder.
The 2026 competition featured two pitch events at the Dairy Arts Center in Boulder, one focused on biosciences and another on physical sciences and engineering. Participating teams presented their commercialization opportunities to judges drawn from the university’s entrepreneurial network.
The 12 funded projects received individual grants ranging from $100,000 to $200,000.
2026 Lab Venture Challenge Award Recipients
Physical Sciences and Engineering
| Startup / Project | Award |
|---|---|
| Fortifyd | $200,000 |
| Orva Energy | $170,000 |
| Ptarmigan Clockworks | $140,000 |
| Choyu Networks | $100,000 |
| RheoSynapse | $100,000 |
| Sonoptic | $100,000 |
| Subtotal | $810,000 |
Biosciences
| Startup / Project | Award |
|---|---|
| AnesaBio | $200,000 |
| Potentis Imaging | $170,000 |
| Sieyax | $140,000 |
| Regelife | $100,000 |
| Enlixa Bio | $100,000 |
| Opera Space | $100,000 |
| Subtotal | $810,000 |
Approach & Ecosystem Context
The Lab Venture Challenge is structured to address a common gap in university commercialization: the limited availability of development capital for technically promising innovations that have not yet reached conventional venture investment readiness.
At this stage, research teams often need resources to refine prototypes, validate technical performance, strengthen intellectual property, demonstrate customer relevance, and establish a viable commercialization strategy.
These activities can be difficult to finance through traditional academic research grants or private investment alone.
LVC combines non-dilutive grant funding with university commercialization support to help bridge this gap.
State-University Funding Partnership
The partnership between Colorado’s OEDIT Advanced Industries Program and Venture Partners at CU Boulder is central to the program’s structure.
State economic development funding is combined with university matching resources to support research-based businesses with potential economic and commercial applications.
This model aligns institutional technology transfer objectives with broader regional economic development priorities.
For the university, the program provides a mechanism to advance intellectual property and support venture formation.
For the state, the program creates opportunities to develop new companies and technologies emerging from publicly supported research.
Venture Development Beyond Grant Funding
LVC is not limited to distributing commercialization grants.
Participating teams work with Venture Partners at CU Boulder to protect their innovations and prepare investment-oriented presentations.
The pitch competition requires researchers to communicate their technologies in terms relevant to prospective customers, investors, and commercial partners.
This process helps translate scientific achievements into business propositions that address market needs.
Winning teams continue working with Venture Partners after the competition as they advance toward commercialization.
This combination of funding, intellectual property support, and venture preparation is an important distinction between LVC and a conventional research grant program.
Commercialization Track Record
Venture Partners reports that LVC has supported more than 155 projects and more than 81 new deep-tech startup companies.
Collectively, these companies have raised more than $691 million in follow-on financing.
The program also highlighted two previous award recipients demonstrating continued commercialization progress.
Arkana Therapeutics, a 2025 biosciences winner developing obesity treatments inspired by an appetite-suppressing compound identified in python blood, has completed a $750,000 pre-seed financing round.
Mesa Quantum, a 2023 physical sciences winner developing chip-scale atomic clocks and quantum sensors, has raised nearly $16 million in venture funding while progressing toward volume manufacturing.
These examples illustrate how early commercialization support can precede additional investment and product development.
However, the reported follow-on financing should not be interpreted as funding generated solely by LVC grants.
Mind the GAP Perspective
The Lab Venture Challenge illustrates an integrated GAP funding model combining institutional commercialization support, state economic development resources, and venture development activities.
Several elements are particularly relevant to university commercialization leaders.
First, the program funds opportunities across multiple technology sectors rather than limiting support to a single research discipline.
Second, award amounts vary according to project needs, allowing the program to allocate different levels of capital across its portfolio.
Third, commercialization support begins before the final funding decision through intellectual property assistance and pitch preparation.
Fourth, the program maintains relationships with participating companies after the awards, supporting continued progress toward external investment and market entry.
Finally, LVC provides an example of how commercialization programs can track long-term outcomes, including company formation and follow-on capital.
The 2026 cohort is notable because most awardees have already formed startup entities, suggesting that the funding is being deployed at a relatively advanced point in the university venture development pathway.
For many of these companies, the next commercialization challenge is not determining whether a startup should exist, but demonstrating that the underlying technology can become a commercially viable product or service.
Innovation & Technology
The 2026 award portfolio includes 12 technologies spanning advanced materials, energy storage, precision timing, cybersecurity, medical devices, therapeutics, and research platforms.
Physical Sciences and Engineering
Fortifyd: Tunable 3D-Printed Helmet Liners
Award: $200,000 | PI: Robert MacCurdy | CEO: Teri Ham
Fortifyd is developing protective helmet liners using a 3D-printed plate-lattice structure designed to manage different types of impact.
The technology addresses limitations associated with conventional helmet foams, particularly the need to manage repeated impacts and rotational forces.
Peer-reviewed research reported up to 10 times greater impact tolerance than conventional foams at equal density under the conditions studied.
The company has formed Fortifyd LLC to commercialize the technology.
Orva Energy: AI-Accelerated Advanced Battery Materials
Award: $170,000 | PI: Chunmei Ban | Co-founder: Evan Flitz
Orva Energy is developing high-energy battery materials using earth-abundant, domestically sourced elements.
The technology combines machine learning and artificial intelligence with advanced crystal-structure engineering to develop materials intended to compete with conventional lithium-based systems.
The commercial opportunity centers on potentially reducing battery material costs while maintaining energy performance.
The company has formed Orva Energy to advance the technology.
Ptarmigan Clockworks: Autonomous Optical Clocks
Award: $140,000 | PI and CEO: Benjamin Hunt
Ptarmigan Clockworks is developing optical clocks designed to operate without the environmental and calibration constraints that have traditionally limited their deployment.
The company aims to translate highly precise laboratory timing technology into manufacturable systems.
Potential applications include distributed sensing, quantum systems, and national security infrastructure.
Ptarmigan Clockworks Inc. has been formed to commercialize the technology.
Choyu Networks: Post-Quantum Cryptography
Award: $100,000 | PI and CTO: Elliot Eichen
Choyu Networks is developing quantum-resistant cryptographic technology for devices and networks with limited computational power or communications bandwidth.
The technology targets environments where emerging post-quantum public-key algorithms may be difficult to implement.
Potential customers include operators of Internet of Things devices and constrained communications infrastructure.
Choyu Networks Inc. has been formed to bring the technology to market.
RheoSynapse: Intelligent Electronic Skin for Prosthetics
Award: $100,000 | PI: Jianliang Xiao
RheoSynapse is developing stretchable liquid-metal electronic skin that can be integrated into prosthetic sockets.
The system maps pressure in real time and uses AI-based analytics to identify patterns associated with potential fit problems.
The technology is intended to help prosthetists improve socket fit and patient comfort.
RheoSynapse Inc. has been formed to commercialize the platform.
Sonoptic: Chip-Scale Acoustic-Optoelectronic Oscillator
Award: $100,000 | PI: Matt Eichenfield
The Sonoptic project is developing a chip-scale microwave oscillator that circulates energy between light and sound waves.
The approach is intended to achieve high signal purity in a compact device without requiring conventional electronic feedback within the oscillator loop.
Potential applications include radar, navigation, and communications systems.
The announcement does not explicitly confirm startup formation for this project.
Biosciences
AnesaBio: Long-Acting Non-Opioid Pain Therapy
Award: $200,000 | PI and CSO: Michael Stowell
AnesaBio is developing a long-acting non-opioid analgesic targeting the CaV3.2 ion channel.
The therapeutic approach aims to provide sustained relief from chronic pain without the abuse liability associated with opioid medications.
The company has formed AnesaBio to advance the technology.
Potentis Imaging: MRI Biomarkers for Cartilage Health
Award: $170,000 | PI: Corey Neu
Potentis Imaging is developing a noninvasive MRI technique designed to detect electrical and mechanical characteristics of cartilage under joint loading.
The approach may enable earlier detection of cartilage degeneration than conventional imaging techniques.
Potential applications include osteoarthritis risk assessment and monitoring the effectiveness of joint-preserving treatments.
Potentis Imaging has been formed to commercialize the technology.
Sieyax: EYA3-Targeted Breast Cancer Therapeutics
Award: $140,000 | PI: Xiang Wang | CEO: Ginny Orndorff
Sieyax is developing targeted molecules intended to degrade EYA3, a protein associated with immune suppression in triple-negative breast cancer.
The research team found that eliminating EYA3 from tumor-associated macrophages reduced tumor size and increased T-cell infiltration in mice.
The company is developing bifunctional molecules intended to reproduce this effect pharmacologically.
These findings remain preclinical.
Regelife: AI-Designed Biomaterials for Regenerative Medicine
Award: $100,000 | PI: Kristi S. Anseth | CEO: Mark Ma
Regelife is developing machine learning-designed biomaterial matrices tailored to specific cell therapy applications.
The technology builds on hydrogel chemistry developed in the Anseth laboratory at CU Boulder.
Its commercial objective is to provide more defined and application-specific alternatives to commonly used cell culture materials such as Matrigel.
Potential applications include regenerative medicine and cell therapy manufacturing.
Enlixa Bio: Real-Time Drug Screening Platform
Award: $100,000 | PI: Dylan Taatjes | CEO: Nik Chopra
Enlixa Bio is commercializing RIFT, a real-time fluorescence-based transcription screening platform developed in the Taatjes laboratory.
The technology enables direct observation of individual drug-target interactions and is intended to distinguish on-target from off-target activity.
The platform could support earlier evaluation of drug candidates targeting transcription regulators.
Opera Space: Microgravity Stem Cell Manufacturing
Award: $100,000 | PI: Tobias Niederwieser | Co-founder: Stuart Tozer
Opera Space is developing a microgravity-based biomanufacturing platform intended to expand umbilical cord blood stem cells.
The technology uses microgravity conditions to keep cells suspended without conventional mechanical agitation.
The research aims to increase the availability of cord blood stem cells for transplantation, particularly for adult patients requiring larger cell quantities.
Opera Space LLC has been formed to advance the technology.
Related Topics
University of Colorado, CU Boulder, Venture Partners at CU Boulder, Lab Venture Challenge, LVC, Colorado OEDIT, Advanced Industries Program, university commercialization, GAP funding, proof-of-concept funding, university spinouts, venture development, technology transfer, deep-tech startups, translational research, Fortifyd, Orva Energy, Ptarmigan Clockworks, Choyu Networks, RheoSynapse, Sonoptic, AnesaBio, Potentis Imaging, Sieyax, Regelife, Enlixa Bio, Opera Space, quantum technology, advanced battery materials, medical devices, biopharma, regenerative medicine, artificial intelligence, university venture funding, commercialization grants, economic development
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
